Switzerland Pharmaceuticals and Healthcare Report Q3 2014 is a new market research publication announced by Reportstack. While the government has enforced price erosion mechanisms on medicines to contain escalating healthcare costs, we note that market growth has been supported by high consumption levels (as a result of an ageing population) and the population's preference for high-value innovative treatments for chronic diseases over lower-value generic medicines. The government operates a generous medicine reimbursement scheme and the country has a swift and sophisticated medicines approvals process. Switzerland is often chosen as a launch market for many innovative medicines, while access to the latest medicines is widespread.
Headline Expenditure Projections
- Pharmaceuticals: CHF7.20bn (US$7.76bn) in 2013 to CHF7.32bn (US$6.84bn) in 2014; +2.1% in local currency terms.
- Healthcare: CHF66.37bn (US$71.62bn) in 2013 to CHF67.81bn (US$63.26bn) in 2014; +2.2% growth in local currency terms.
To view the table of contents and know more details please visit Switzerland Pharmaceuticals and Healthcare Report Q3 2014.